-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to Flush data statistics, as of December 3, a total of 89 listed companies have announced their 2021 annual performance forecasts
.
Among them, 54 companies are expected to increase, accounting for more than 60%
.
In addition, 1 company turned losses, 1 company reduced losses, 1 company increased losses, 6 companies had a pre-profit, 1 company had a pre-loss, and 9 companies had a pre-fall
.
From the perspective of pre-increasing industries, the main focus is on industries such as pharmaceuticals, biology, electronics, chemicals, and machinery and equipment
.
In the pharmaceutical and biological industry, there are currently 7 listed companies that have disclosed their 2021 annual performance forecasts.
Among them, 5 companies are expected to increase their performance, including Enhua Pharmaceutical, Zuoli Pharmaceutical, Hualan, Baicheng Pharmaceutical, Jiahe Meikang, etc.
, another one has turned losses, and one is expected to reduce losses
.
The lower limit of the net profit of the two pharmaceutical companies exceeds 1 billion yuan.
From the perspective of the expected lower limit of net profit, there are 4 companies with a net profit of more than 500 million yuan, namely Yanan Bikang, Enhua Pharmaceutical, Zuoli Pharmaceutical, Hualan has two companies with a net profit of more than 1 billion yuan, namely Zuoli Pharmaceutical and Hualan
.
Among them, Zuoli Pharmaceutical expects to have a substantial increase in 2021 annual performance.
The annual performance forecast disclosed by the company on October 27 shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 170 million yuan to 187 million yuan.
A year-on-year increase of 91.
44-110.
58%
.
According to data, Zuoli Pharmaceutical is mainly based on the production of modern biological Chinese medicine products based on medicinal fungal bio-fermentation technology.
It is currently engaged in the research, production and marketing of medicinal fungi Wuling and Bailing series products, Lingze tablets, Chinese medicine decoction pieces and Chinese medicine formula granules
.
Hualan shares are mainly engaged in the research, production and marketing of packaging materials for direct contact injection drugs
.
Although the company is a sub-new stock that has been listed for less than a month, the company expects that its 2021 annual performance will also rise sharply.
It is expected to achieve a net profit of 197 million yuan to 266 million yuan attributable to the parent in 2021, an increase of 141.
64% to 226.
92% year-on-year
.
It is worth mentioning that Yan'an Bikang is expected to turn around in its full-year performance.
On October 29, Yan'an Bikang issued a 2021 annual performance forecast with an estimated net profit of 950 million yuan to 1 billion yuan.
.
The company's main business includes the pharmaceutical industry sector, pharmaceutical commercial sector, new energy and new materials sector and pharmaceutical intermediates
.
The net profit growth rate of 4 pharmaceutical companies exceeded 50%.
From the point of view of the net profit growth rate, based on the estimated lower limit of the net profit growth rate, a total of 4 companies’ net profit growth rate exceeded 50%.
For Li Pharmaceutical and Baicheng Pharmaceutical, the lower limit of net profit increased by 188.
72%, 141.
64%, 91.
44%, and 72.
46% respectively
.
Among them, some pharmaceutical companies explained the reasons for their performance growth in the announcement
.
For example, Yan'an Bikang explained the reasons for the growth in performance, saying that the new energy products of its subsidiary Jiangsu Jiujiu Technology Co.
, Ltd.
were affected by market demand, the release of production capacity, and the rise in market prices, etc.
, caused the increase in profits and the company’s performance growth.
Play a positive role in promoting; due to the release of production capacity and other reasons, the profit of the new materials sector has also increased
.
In addition, the company's subsidiaries received relevant subsidies, which had a greater impact on profits
.
The performance of the four pharmaceutical companies is expected to decline.
Some people are happy, but naturally some are worried
.
There are 4 pharmaceutical and biological companies that have predicted a reduction in their annual performance.
Among them, Dizhe Pharmaceutical is expected to increase losses, with annual net profit of 680 million yuan to 610 million yuan, which is -15.
92% compared with the same period of the previous year.
.
Berry Gene announced its performance pre-loss company on October 30.
It is estimated that the annual net profit will be -90 million yuan to -60 million yuan.
Compared with the same period last year, the net profit will drop by 143% to 128%
.
Tuoxin Pharmaceutical's annual performance is also expected to decline.
It is expected that the net profit for the year of 2021 will be 78 million yuan to 98 million yuan, a decrease of 30.
85% to 13.
12%
.
In addition, Hendy Pharmaceuticals expects annual net profit of 130 million to 140 million yuan, compared with the same period of the previous year, the decline in net profit is 22.
65% to 16.
7%
.
Attachment: List of annual performance forecasts for the pharmaceutical and biological industry
.
Among them, 54 companies are expected to increase, accounting for more than 60%
.
In addition, 1 company turned losses, 1 company reduced losses, 1 company increased losses, 6 companies had a pre-profit, 1 company had a pre-loss, and 9 companies had a pre-fall
.
From the perspective of pre-increasing industries, the main focus is on industries such as pharmaceuticals, biology, electronics, chemicals, and machinery and equipment
.
In the pharmaceutical and biological industry, there are currently 7 listed companies that have disclosed their 2021 annual performance forecasts.
Among them, 5 companies are expected to increase their performance, including Enhua Pharmaceutical, Zuoli Pharmaceutical, Hualan, Baicheng Pharmaceutical, Jiahe Meikang, etc.
, another one has turned losses, and one is expected to reduce losses
.
The lower limit of the net profit of the two pharmaceutical companies exceeds 1 billion yuan.
From the perspective of the expected lower limit of net profit, there are 4 companies with a net profit of more than 500 million yuan, namely Yanan Bikang, Enhua Pharmaceutical, Zuoli Pharmaceutical, Hualan has two companies with a net profit of more than 1 billion yuan, namely Zuoli Pharmaceutical and Hualan
.
Among them, Zuoli Pharmaceutical expects to have a substantial increase in 2021 annual performance.
The annual performance forecast disclosed by the company on October 27 shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 170 million yuan to 187 million yuan.
A year-on-year increase of 91.
44-110.
58%
.
According to data, Zuoli Pharmaceutical is mainly based on the production of modern biological Chinese medicine products based on medicinal fungal bio-fermentation technology.
It is currently engaged in the research, production and marketing of medicinal fungi Wuling and Bailing series products, Lingze tablets, Chinese medicine decoction pieces and Chinese medicine formula granules
.
Hualan shares are mainly engaged in the research, production and marketing of packaging materials for direct contact injection drugs
.
Although the company is a sub-new stock that has been listed for less than a month, the company expects that its 2021 annual performance will also rise sharply.
It is expected to achieve a net profit of 197 million yuan to 266 million yuan attributable to the parent in 2021, an increase of 141.
64% to 226.
92% year-on-year
.
It is worth mentioning that Yan'an Bikang is expected to turn around in its full-year performance.
On October 29, Yan'an Bikang issued a 2021 annual performance forecast with an estimated net profit of 950 million yuan to 1 billion yuan.
.
The company's main business includes the pharmaceutical industry sector, pharmaceutical commercial sector, new energy and new materials sector and pharmaceutical intermediates
.
The net profit growth rate of 4 pharmaceutical companies exceeded 50%.
From the point of view of the net profit growth rate, based on the estimated lower limit of the net profit growth rate, a total of 4 companies’ net profit growth rate exceeded 50%.
For Li Pharmaceutical and Baicheng Pharmaceutical, the lower limit of net profit increased by 188.
72%, 141.
64%, 91.
44%, and 72.
46% respectively
.
Among them, some pharmaceutical companies explained the reasons for their performance growth in the announcement
.
For example, Yan'an Bikang explained the reasons for the growth in performance, saying that the new energy products of its subsidiary Jiangsu Jiujiu Technology Co.
, Ltd.
were affected by market demand, the release of production capacity, and the rise in market prices, etc.
, caused the increase in profits and the company’s performance growth.
Play a positive role in promoting; due to the release of production capacity and other reasons, the profit of the new materials sector has also increased
.
In addition, the company's subsidiaries received relevant subsidies, which had a greater impact on profits
.
The performance of the four pharmaceutical companies is expected to decline.
Some people are happy, but naturally some are worried
.
There are 4 pharmaceutical and biological companies that have predicted a reduction in their annual performance.
Among them, Dizhe Pharmaceutical is expected to increase losses, with annual net profit of 680 million yuan to 610 million yuan, which is -15.
92% compared with the same period of the previous year.
.
Berry Gene announced its performance pre-loss company on October 30.
It is estimated that the annual net profit will be -90 million yuan to -60 million yuan.
Compared with the same period last year, the net profit will drop by 143% to 128%
.
Tuoxin Pharmaceutical's annual performance is also expected to decline.
It is expected that the net profit for the year of 2021 will be 78 million yuan to 98 million yuan, a decrease of 30.
85% to 13.
12%
.
In addition, Hendy Pharmaceuticals expects annual net profit of 130 million to 140 million yuan, compared with the same period of the previous year, the decline in net profit is 22.
65% to 16.
7%
.
Attachment: List of annual performance forecasts for the pharmaceutical and biological industry
